All In Biotech

Drug Trial Radar · NCT07298395

Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 12-Week Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ENV-294 in Adult Participants With Moderate-to-Severe Atopic Dermatitis

Last checked: Nov 19, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 105 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

105

Planned (sponsor's estimate)

Start

Dec 22, 2025

Primary completion

Dec 2026

Study completion Dec 2026

Sponsor

Lead sponsor
Enveda TherapeuticsIndustry
Sponsor type
Industry
First posted
Dec 23, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn about the safety and effectiveness of ENV-294 in adults with moderate to severe atopic dermatitis. The main questions it will answer are: * Is there an impact on the severity and area of atopic dermatitis when participants take ENV-294 * What medical problems do participants have when taking ENV-294 Participants will: * Take drug ENV-294 or a placebo once every day for 12 weeks * Visit the clinic every 2 to 4 weeks for checkups and tests * Keep a diary of their symptoms and when they took their study drug * Return to the clinic for the final study visit at approximately week 16

Conditions

  • Atopic Dermatitis (AD)

Interventions

  • ENV-294Drug

    ENV-294 is an orally administered investigational drug supplied as tablets. Participants receive ENV-294 once daily by mouth for 12 weeks.

  • PlaceboDrug

    Matching oral tablet that does not contain active drug. Administered once daily by mouth for 12 weeks under the same conditions as the investigational product.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the efficacy of ENV-294 compared to placebo on severity and extent of atopic dermatitis (AD)Time frame: Baseline to Week 12

Locations

32 sites in 1 country. Site status is shown where the registry gives one.

  • Enveda Investigative Site

    Birmingham, Alabama · Recruiting

  • Enveda Investigative Site

    Hot Springs, Arkansas · Recruiting

  • Enveda Investigative Site

    Beverly Hills, California · Recruiting

  • Enveda Investigative Site

    Fremont, California · Recruiting

  • Enveda Investigative Site

    San Diego, California · Recruiting

  • Enveda Investigative Site

    San Diego, California · Recruiting

  • Enveda Investigative Site

    Santa Monica, California · Recruiting

  • Enveda Investigative Site

    West Hills, California · Recruiting

  • Enveda Investigative Site

    Fort Lauderdale, Florida · Recruiting

  • Enveda Investigative Site

    Miami, Florida · Recruiting

  • Enveda Investigative Site

    Miramar, Florida · Recruiting

  • Enveda Investigative Site

    Atlanta, Georgia · Recruiting

  • Enveda Investigative Site

    Chicago, Illinois · Recruiting

  • Enveda Investigative Site

    Clarksville, Indiana · Recruiting

  • Enveda Investigative Site

    New Albany, Indiana · Recruiting

  • Enveda Investigative Site

    West Lafayette, Indiana · Recruiting

  • Enveda Investigative Site

    Louisville, Kentucky · Recruiting

  • Enveda Investigative Site

    Louisville, Kentucky · Recruiting

  • Enveda Investigative Site

    Auburn Hills, Michigan · Recruiting

  • Enveda Investigative Site

    Bay City, Michigan · Recruiting

  • Enveda Investigative Site

    Clinton Township, Michigan · Recruiting

  • Enveda Investigative Site

    Warren, Michigan · Recruiting

  • Enveda Investigative Site

    Las Vegas, Nevada · Recruiting

  • Enveda Investigative Site

    New York, New York · Recruiting

  • Enveda Investigative Site

    Wilmington, North Carolina · Recruiting

  • Enveda Investigative Site

    Canton, Ohio · Recruiting

  • Enveda Investigative Site

    Mayfield Heights, Ohio · Recruiting

  • Enveda Investigative Site

    Camp Hill, Pennsylvania · Recruiting

  • Enveda Investigative Site

    Arlington, Texas · Recruiting

  • Enveda Investigative Site

    Houston, Texas · Recruiting

  • Enveda Investigative Site

    San Antonio, Texas · Recruiting

  • Enveda Investigative Site

    Norfolk, Virginia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.